Curi RMB Capital’s Myriad Genetics MYGN Stock Holding History

Curi RMB Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-27,211	Closed	-$903K	–	808
2019 Q1	$903K	Buy	+27,211	New	+$828K	0.02%	470

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Curi RMB Capital's MYGN Position: Q2 2019 in Review

Curi RMB Capital sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 27,211 shares — an estimated $903K sold.

Curi RMB Capital first reported a position in MYGN in Q1 2019 and held it in 1 quarter. The position peaked at $903K in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Curi RMB Capital reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Curi RMB Capital sold 27,211 Myriad Genetics shares in Q2 2019, an estimated $903K.
Curi RMB Capital first reported a position in Myriad Genetics in Q1 2019 and held it in 1 quarter.
Curi RMB Capital's Myriad Genetics position peaked at $903K in Q1 2019.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Curi RMB Capital's 13F filing for Q2 2019, filed 13 Aug 2019.